U.S. markets open in 7 hours 7 minutes
  • S&P Futures

    4,573.50
    -2.25 (-0.05%)
     
  • Dow Futures

    34,644.00
    +22.00 (+0.06%)
     
  • Nasdaq Futures

    15,969.75
    -18.75 (-0.12%)
     
  • Russell 2000 Futures

    2,200.30
    -4.90 (-0.22%)
     
  • Crude Oil

    67.66
    +1.16 (+1.74%)
     
  • Gold

    1,771.90
    +9.20 (+0.52%)
     
  • Silver

    22.43
    +0.15 (+0.67%)
     
  • EUR/USD

    1.1289
    -0.0017 (-0.15%)
     
  • 10-Yr Bond

    1.4480
    0.0000 (0.00%)
     
  • Vix

    27.95
    -3.17 (-10.19%)
     
  • GBP/USD

    1.3278
    -0.0024 (-0.18%)
     
  • USD/JPY

    113.2900
    +0.0810 (+0.07%)
     
  • BTC-USD

    56,792.49
    -175.99 (-0.31%)
     
  • CMC Crypto 200

    1,445.74
    +6.86 (+0.48%)
     
  • FTSE 100

    7,129.21
    -39.47 (-0.55%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Inspire Medical Systems, Inc. to Report Third Quarter 2020 Financial Results on November 2, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MINNEAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2020 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Monday, November 2rd @ 5:00 p.m. Eastern Time:

Domestic:

877-407-0792

International:

201-689-8263

Conference ID:

13710653

Webcast:

http://public.viavid.com/index.php?id=141564

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989